Brief: Pharming Group Completes Enrollment In Pediatric Clinical Trial Of Leniolisib
08/04/2024 06:06
April 8 (Reuters) - Pharming Group NV PHAR.AS :
* PHARMING ANNOUNCES COMPLETION OF ENROLLMENT IN PEDIATRIC
CLINICAL TRIAL OF LENIOLISIB
* THIS MULTINATIONAL PHASE III STUDY IS EVALUATING
LENIOLISIB
TABLETS IN CHILDREN AGED 4 TO 11 YEARS WITH APDS, A RARE PRIMARY
IMMUNODEFICIENCY
* PHARMING PLANS TO INCLUDE DATA FROM THIS 4–11-YEAR-OLD
TRIAL IN
REGULATORY FILINGS WORLDWIDE FOR THE APPROVAL OF LENIOLISIB FOR
PEDIATRIC PATIENTS WITH APDS, BEGINNING IN 2025
Source text for WorkSpace: urn:newsml:reuters.com:*:nGNE4zk3wS
Further company coverage: PHAR.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))